NFSG
PVLA

Newbridge Financial Services Group’s Palvella Therapeutics PVLA Stock Holding History

Newbridge Financial Services Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115 Buy
+1
New +$121 ﹤0.01% 1195
2021
Q3 		– Sell
-100
Closed -$31K – 1635
2021
Q2 		$31K Hold
100
– – 0.02% 625
2021
Q1 		$21K Hold
100
– – 0.02% 686
2020
Q4 		$20K Hold
100
– – 0.02% 548
2020
Q3 		$17K Buy
+100
New +$22.8K 0.02% 552

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Newbridge Financial Services Group's PVLA Position: Q2 2026 in Review

Newbridge Financial Services Group opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 1 share worth $115. The stake represents ﹤0.01% of the portfolio and ranks #1195 among its holdings. This is a return to the name: Newbridge Financial Services Group previously reported a position in PVLA as recently as Q2 2021.

Newbridge Financial Services Group first reported a position in PVLA in Q3 2020 and has held it in 5 quarters since. The position peaked at $31K in Q2 2021. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Newbridge Financial Services Group held 1 share of Palvella Therapeutics worth $115 as of Q2 2026.
  • Palvella Therapeutics was a new Newbridge Financial Services Group position in Q2 2026.
  • Palvella Therapeutics made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q2 2026, its #1195 holding.
  • Newbridge Financial Services Group first reported a position in Palvella Therapeutics in Q3 2020 and has held it in 5 quarters since.
  • Newbridge Financial Services Group's Palvella Therapeutics position peaked at $31K in Q2 2021.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Newbridge Financial Services Group's 13F filing for Q2 2026, filed 14 Aug 2026.